JP7530904B2 - 特異的結合性分子 - Google Patents

特異的結合性分子 Download PDF

Info

Publication number
JP7530904B2
JP7530904B2 JP2021544406A JP2021544406A JP7530904B2 JP 7530904 B2 JP7530904 B2 JP 7530904B2 JP 2021544406 A JP2021544406 A JP 2021544406A JP 2021544406 A JP2021544406 A JP 2021544406A JP 7530904 B2 JP7530904 B2 JP 7530904B2
Authority
JP
Japan
Prior art keywords
binding molecule
specific binding
amino acid
acid sequence
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021544406A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020157210A5 (https=
JP2022523507A5 (https=
JP2022523507A (ja
Inventor
コネストラーロ，マルティナ
ディークマン，ネレ
ハーパー，スティーブン
ベネディクト カーク，ピーター
マルバニー，レイチェル
オドワイヤー，ローナン
バトラー ロバートソン，イアン
Original Assignee
イムノコア リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イムノコア リミテッド filed Critical イムノコア リミテッド
Publication of JP2022523507A publication Critical patent/JP2022523507A/ja
Publication of JPWO2020157210A5 publication Critical patent/JPWO2020157210A5/ja
Publication of JP2022523507A5 publication Critical patent/JP2022523507A5/ja
Application granted granted Critical
Publication of JP7530904B2 publication Critical patent/JP7530904B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/33—Antibodies; T-cell engagers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
JP2021544406A 2019-01-30 2020-01-30 特異的結合性分子 Active JP7530904B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1901305.1 2019-01-30
GBGB1901305.1A GB201901305D0 (en) 2019-01-30 2019-01-30 Specific binding molecules
PCT/EP2020/052315 WO2020157210A1 (en) 2019-01-30 2020-01-30 Cd3-specific binding molecules

Publications (4)

Publication Number Publication Date
JP2022523507A JP2022523507A (ja) 2022-04-25
JPWO2020157210A5 JPWO2020157210A5 (https=) 2023-03-10
JP2022523507A5 JP2022523507A5 (https=) 2023-03-10
JP7530904B2 true JP7530904B2 (ja) 2024-08-08

Family

ID=65997940

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021544406A Active JP7530904B2 (ja) 2019-01-30 2020-01-30 特異的結合性分子

Country Status (12)

Country Link
US (1) US12590152B2 (https=)
EP (1) EP3917959A1 (https=)
JP (1) JP7530904B2 (https=)
KR (1) KR20210121141A (https=)
CN (1) CN113728005B (https=)
AU (1) AU2020215776A1 (https=)
BR (1) BR112021014963A2 (https=)
CA (1) CA3127144A1 (https=)
GB (1) GB201901305D0 (https=)
IL (1) IL284926B2 (https=)
MX (1) MX2021009275A (https=)
WO (1) WO2020157210A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12162940B2 (en) 2021-05-05 2024-12-10 Immatics Biotechnologies Gmbh BMA031 antigen binding polypeptides
CN115724988B (zh) * 2021-08-26 2023-11-17 瑅安生物医药（杭州）有限公司 一种接近天然分子的多肽融合分子
KR20240149435A (ko) 2022-02-20 2024-10-14 이뮤노코어 리미티드 Hiv 특이적 결합 분자
MX2025001960A (es) 2022-08-18 2025-05-02 Immunocore Ltd Moléculas de unión multidominio
US12134647B2 (en) 2023-01-06 2024-11-05 Immunocore Limited Binding molecules
US12195534B2 (en) 2023-01-06 2025-01-14 Immunocore Limited Binding molecules
TW202519257A (zh) * 2023-08-01 2025-05-16 英商英美偌科有限公司 治療皮膚黑色素瘤之方法
WO2025050404A1 (zh) * 2023-09-08 2025-03-13 成都维瑾柏鳌生物医药科技有限公司 一种药物组合物及其应用
GB202320012D0 (en) 2023-12-22 2024-02-07 Immunocore Ltd Bispecific molecules
GB2641580A (en) 2024-06-07 2025-12-10 T Therapeutics Ltd Tumour-transforming multispecific proteins
WO2026078231A1 (en) 2024-10-11 2026-04-16 T-Therapeutics Limited Soluble non-aggregating immune ligand

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018234319A1 (en) 2017-06-20 2018-12-27 Immunocore Limited T cell receptors

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US36676A (en) 1862-10-14 Improvement in grain-cleaners
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
AU7757581A (en) 1980-11-19 1982-05-27 United Energy Technologies Inc. Enhanced surface tubing
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
JPS5855530Y2 (ja) 1981-06-15 1983-12-20 松下電工株式会社 照明器具を有する天井
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4630115A (en) 1983-05-09 1986-12-16 The General Electric Company, P.L.C. Cathode ray tube display device
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
AU6685698A (en) 1997-03-07 1998-09-22 Sunol Molecular Corporation Fusion proteins comprising bacteriophage coat protein and a single-chain t cell receptor
WO1999018129A1 (en) 1997-10-02 1999-04-15 Sunol Molecular Corporation Soluble single-chain t-cell receptor proteins
WO2001062908A2 (en) 2000-02-22 2001-08-30 Ahuva Nissim Chimeric and tcr phage display libraries, chimeric and tcr reagents and methods of use thereof
CN101289511A (zh) 2000-04-11 2008-10-22 杰南技术公司 多价抗体及其应用
AU2002321581C1 (en) 2001-08-31 2008-09-18 Adaptimmune Limited Soluble T cell receptor
AU2003271904B2 (en) 2002-10-09 2009-03-05 Adaptimmune Limited Single chain recombinant T cell receptors
US8361794B2 (en) 2004-06-29 2013-01-29 Immunocore Limited Cells expressing a modified T cell receptor
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
GB0908613D0 (en) * 2009-05-20 2009-06-24 Immunocore Ltd T Cell Reseptors
GB0911566D0 (en) 2009-07-03 2009-08-12 Immunocore Ltd T cell receptors
WO2014012085A2 (en) 2012-07-13 2014-01-16 Zymeworks Inc. Bispecific asymmetric heterodimers comprising anti-cd3 constructs
UA129760C2 (uk) * 2013-12-17 2025-07-30 Дженентек, Інк. Анти-cd3 антитіло та спосіб його застосування
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card
GB201522592D0 (en) 2015-12-22 2016-02-03 Immunocore Ltd T cell receptors
PL3440105T3 (pl) 2016-04-08 2022-08-29 Immunocore Limited Receptory komórek t
GB201915282D0 (en) * 2019-10-22 2019-12-04 Immunocore Ltd Specific binding molecules
GB202006629D0 (en) * 2020-05-05 2020-06-17 Immunocore Ltd Specific binding molecules
US12103971B2 (en) * 2022-02-20 2024-10-01 Immunocore Limited HIV specific binding molecules
CA3265218A1 (en) * 2022-08-18 2024-02-22 Immunocore Ltd MAGE A4 SPECIFIC T LYMPHOCYTE RECEPTOR FUSION PROTEINS
US12195534B2 (en) * 2023-01-06 2025-01-14 Immunocore Limited Binding molecules
US12134647B2 (en) * 2023-01-06 2024-11-05 Immunocore Limited Binding molecules

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018234319A1 (en) 2017-06-20 2018-12-27 Immunocore Limited T cell receptors

Also Published As

Publication number Publication date
BR112021014963A2 (pt) 2021-09-28
EP3917959A1 (en) 2021-12-08
GB201901305D0 (en) 2019-03-20
CA3127144A1 (en) 2020-08-06
WO2020157210A1 (en) 2020-08-06
IL284926A (en) 2021-09-30
KR20210121141A (ko) 2021-10-07
CN113728005B (zh) 2025-02-21
AU2020215776A1 (en) 2021-09-09
US20220119527A1 (en) 2022-04-21
CN113728005A (zh) 2021-11-30
MX2021009275A (es) 2021-08-16
US12590152B2 (en) 2026-03-31
IL284926B1 (en) 2025-11-01
JP2022523507A (ja) 2022-04-25
IL284926B2 (en) 2026-03-01

Similar Documents

Publication Publication Date Title
JP7530904B2 (ja) 特異的結合性分子
US11859004B2 (en) Anti-human 4-1BB antibodies and uses thereof
JP7720685B2 (ja) Ｔ細胞レセプター
JP7143452B2 (ja) ＣＤ４７とＳＩＲＰａの相互作用を遮断できる抗体及びその応用
US11518808B2 (en) Anti-PD-1 antibodies and methods of treatment
CN107223135B (zh) 用于治疗hbv感染和相关病症的三特异性结合分子
JP2020018298A (ja) Ｃｌｄｎ１８．２及びｃｄ３に対する抗体コンストラクト
JP2022101631A (ja) 抗ｐｄ‐ｌ１抗体とｉｌ‐７との融合
JP2019514871A (ja) 骨髄性白血病の治療方法で使用するための、ｃｄ３３とｃｄ３に結合する二重特異性構築物の投与の方法
CN118878694A (zh) 一种双特异性抗体及其用途
TW201916890A (zh) 抗ｐｄ－１抗體和抗ｌａｇ－３抗體聯合在製備治療腫瘤的藥物中的用途
JP2025170264A (ja) 抗ｂｃｍａ剤のための投与レジメン
CN109929037B (zh) 针对程序性死亡配体的结合物及其应用
WO2019192493A1 (zh) 抗人lag-3单克隆抗体及其应用
US20210277139A1 (en) Ifn-gamma-inducible regulatory t cell convertible anti-cancer (irtca) antibody and uses thereof
WO2023236991A1 (zh) 靶向her2，pd-l1和vegf的三特异性抗体
JP7849048B2 (ja) Ｃｄ２５偏向抗ｉｌ－２抗体
WO2024235317A1 (zh) 结合lilrb4和cd3的抗体及其用途
RU2826453C2 (ru) Cd3-специфические связывающие молекулы
WO2023052541A1 (en) Combination of an anti-btn3a activating antibody and an il-2 agonist for use in therapy
WO2025113640A1 (zh) 结合lilrb1/2或pd1-lilrb1/2的抗体及其用途
TW202235436A (zh) Ｓｉｇｌｅｃ－１５結合蛋白的製備及其用途
HK40059424B (zh) 抗cd79b抗体、其抗原结合片段及其医药用途
HK40037194A (en) Anti-pd-1 antibodies and methods of treatment
HK40037194B (en) Anti-pd-1 antibodies and methods of treatment

Legal Events

Date Code Title Description
RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20221128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230130

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230130

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230119

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240415

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240702

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240729

R150 Certificate of patent or registration of utility model

Ref document number: 7530904

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150